- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Schorndorf facility expansion
Catalent?s recent expansion at its Schorndorf, Germany facility enables even better solutions for its customers? most difficult bioavailability, controlled release or targeted delivery profile challenges.
Catalent Pharma Solutions continues to expand its drug development and delivery capabilities to help customers bring better treatments to patients through innovative controlled release technologies, with significant investments at its Schorndorf, Germany facility. Highlights of the recent expansion include the addition of R&D and commercial scale fluid bed technology, OptiMeltTM hot melt extrusion and elevated cGMP compliance for handling of OEB class 3 customer products.
With these capabilities, Catalent Schorndorf is now even better positioned to deliver solutions to their customers’ most difficult bioavailability, controlled release or targeted delivery profile challenges.
The Schorndorf expansion follows recent investments in OSDrC® OptiDoseTM controlled release dose delivery at Catalent’s Winchester, Kentucky, US facility and Lyopan® fast-dissolve lyophilized tablet technology, underlining Catalent’s commitment to innovation and furthering its position as the industry’s leading global partner in oral drug delivery technologies. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs more than 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue.Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.